ProCE Banner Activity

FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96

Slideset Download
Conference Coverage
Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.

Released: March 11, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

Merck & Co., Inc.

ViiV Healthcare